Natasha Mehta, MD
Advanced Heart Failure and Transplant Cardiology · Tampa, FLNPI 1124466453
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,023 of the $32,751 with a category attached, or 73.3%. Alnylam Pharmaceuticals Inc. accounts for 74.9% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $28,801, more than ten times the $1,189 reported in 2019.
Across 129 payments — averaging $253.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$25K
- Cvrx, Inc.$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Medtronic$1K
- Abbott$604
- Abiomed$505
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$24,02373%
- Travel & lodging$3,15410%
- Food & beverage$5,57517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 29 | $24,523 |
| Cvrx, Inc. | 18 | $2,394 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $2,023 |
| Medtronic(2 entities) | 8 | $1,493 |
| Abbott | 8 | $604 |
| Abiomed | 5 | $505 |
| Impulse Dynamics (USA) Inc. | 2 | $251 |
| AstraZeneca | 2 | $178 |
| Sanofi-aventis U.S. LLC | 3 | $157 |
| Pfizer | 6 | $132 |
| Bridgebio Pharma, Inc. | 1 | $120 |
| AbbVie | 1 | $118 |
| W. L. Gore & Associates, Inc. | 1 | $84 |
| Novartis | 5 | $72 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Amgen | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$24,360
- Barostim Neo System$1,933
- LifeVest$1,500
- OPTIMIZER$502
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$381
- Impella$263
- COREVALVE EVOLUT R$210
- Micra$150
- CARDIOMEMS$128
- FARXIGA$122
- Attruby$120
- BOTOX$118
- TZIELD$118
- VYNDAQEL$100
How this compares
$32,751 in reported general payments places this provider in the 70th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 137 | $136,873 |
| FarxigaDapagliflozin Propanediol | 77 | $69,571 |
| EliquisApixaban | 66 | $62,405 |
| JardianceEmpagliflozin | 45 | $39,694 |
| Metoprolol Succinate | 161 | $1,040 |
| Bumetanide | 16 | $809 |
| Carvedilol | 63 | $793 |
| Spironolactone | 76 | $639 |
| Amiodarone Hcl | 24 | $537 |
| Rosuvastatin Calcium | 37 | $495 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 27 | $324 |
| Atorvastatin Calcium | 39 | $309 |
| Furosemide | 45 | $280 |
| Valsartan | 28 | $279 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $72 | $136,873137 claims |
| AstraZenecaFarxiga | $178 | $69,57177 claims |
| PfizerEliquis | $132 | $62,40566 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Tampa
- Stephanie MattathilTampa$6K
- Gabrielle ThomasTampa$921
- Mackenzie ElliottTampa$295
- Kelly McCantsWinter Park$445K
- Naveen BellamOrlando$414K
- Phillip HabibDelray Beach$305K
- Waqas GhummanAtlantis$276K
- David SnipeliskyWeston$250K
- Elsy NavasNaples$234K
- David BaranWeston$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.